
Claims:

1. A pharmaceutical composition comprising an effective amount of nordihydroguaiaretic acid (NDGA) or a derivative thereof of formula I:



(I);

wherein R_1, R_2, R_3 and R_4 independently represent hydroxy, a straight or branched chain lower alkyl or alkoxy, an amino acid residue, a substituted amino acid residue, a nitrogen-containing 5- or 6-membered heterocyclic ring or a saccharide residue; the amino acid residue, substituted amino acid residue, nitrogen-containing 5 or 6 membered heterocyclic ring or saccharide residue being optionally joined to the phenyl ring by a linker of an oxygen atom and 1-10 carbon atoms;

and an effective amount of sorafenib.

2. The pharmaceutical composition of claim 1 comprising tetra-o-methyl nordihydroguaiaretic acid (M4N) or maltose-M3N.

3. Use of the pharmaceutical composition of either of claims 1 or 2 in an amount effective for use in a medicament, and most preferably for use as a medicament for treating a disease or disorder associated with a neoplastic disease in a subject.

4. The use of claim 3 wherein the subject is a human, cat, dog or mouse.

5. The use of either of claims 3 or 4, wherein the neoplastic disease is a tumor and/or its micro and macrometastases.

6. The use any of claims 3 to 5, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor and/or its micro and macrometastases is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

7. Use of the pharmaceutical composition of either of claims 1 or 2 in an amount effective for use in a medicament, and most preferably for use as a medicament for preventing or inhibiting tumor and/or its micro and macrometastatic growth in a subject.

8. The use of claim 7 wherein the NDGA derivative is tetra-*O*-methyl nordihydroguaiaretic acid (M_4N) or maltose-M_3N.

9. The use of either of claim 7 or 8 wherein the subject is a human, cat, dog or mouse.


10. The use of any of claims 7 to 9, wherein the neoplastic disease is a tumor.

11. The use any of claims 7 to 10, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

12. The use any of claims 7 to 11, wherein the pharmaceutical compositions comprise an additional therapeutic agent.

CLAIMS

1. A pharmaceutical composition comprising an effective amount of nordihydroguaiaretic acid (NDGA) or a compound of formula I:



(I);

wherein R_1, R_2, R_3 and R_4 independently represent hydroxy, a straight or branched chain lower alkyl or alkoxy, an amino acid residue, a substituted amino acid residue, a nitrogen-containing 5- or 6-membered heterocyclic ring or a saccharide residue; the amino acid residue, substituted amino acid residue, nitrogen-containing 5 or 6 membered heterocyclic ring or saccharide residue being optionally joined to the phenyl ring by a linker of an oxygen atom and 1-10 carbon atoms;

and a synergistically effective amount of sorafenib.

2. The pharmaceutical composition of claim 1 comprising tetra-*O*-methyl nordihydroguaiaretic acid (M_4N) or maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M_3N).

3. Use of the pharmaceutical composition of either of claims 1 or 2 in an amount effective for treating a disease or disorder associated with a neoplastic disease in a subject.

4. The use of claim 3 wherein the subject is a human, cat, dog or mouse.

5. The use of either of claims 3 or 4, wherein the neoplastic disease is a tumor and/or its micro and macrometastases.

6. The use any of claims 3 to 5, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor and/or its micro and macrometastases is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

7. Use of the pharmaceutical composition of either of claims 1 or 2 in an amount effective for preventing or inhibiting a tumor and/or its micro and macrometastatic growth in a subject.

8. The use of claim 7 wherein the compound is tetra-O-methyl nordihydroguaiaretic acid (M_4N) or maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M_3N).

9. The use of either of claim 7 or 8 wherein the subject is a human, cat, dog or mouse.

10. The use of any of claims 7 to 9, wherein the neoplastic disease is a tumor.

11. The use any of claims 7 to 10, wherein the tumor is a solid tumor, a hematological tumor, or wherein the tumor is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colon cancer, hepatoma, glioblastoma, ovarian cancer, leukemia, Hodgkin's lymphoma and multiple myeloma.

12. The use any of claims 7 to 11, wherein the pharmaceutical compositions comprise an additional therapeutic agent.